Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 4/20 | 0.38 |
| ▸ | JAK3 | P52333 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 4/20 | 0.35 |
| ▸ | LYN | P07948 | 3/20 | 0.35 |
| ▸ | BCR | P11274 | 2/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | ARAF | P10398 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.35 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.35 |
| ▸ | CSK | P41240 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3600363 | 0.83 | LCK (0.39) | KMT2AMEN1L3MBTL1LCKJAK3 | |
| SCHEMBL14020133 | 0.81 | CDK2 (0.37) | JAK3 | |
| SCHEMBL4874632 | 0.80 | CDK2 (0.39) | L3MBTL1JAK3POLB | |
| SCHEMBL3302436 | 0.80 | IKBKB (0.44) | KMT2AMEN1SYKAURKA | |
| SCHEMBL3596730 | 0.79 | IGF1R (0.49) | LCKJAK3AURKAJAK1 | |
| SCHEMBL3610904 | 0.79 | USP30 (0.46) | LCKJAK3SYKMAPK14AURKA | |
| SCHEMBL13392031 | 0.77 | AXL (0.40) | KMT2AMEN1JAK3PDGFRB | |
| SCHEMBL3604003 | 0.77 | PTK2 (0.49) | LCKJAK3SYKAURKAJAK1 | |
| SCHEMBL13502766 | 0.74 | KMT2A (0.47) | KMT2AMEN1L3MBTL1POLB | |
| SCHEMBL4880324 | 0.74 | CDK2 (0.39) | L3MBTL1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035907-A1 | NEW 2,4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | claimed |
| EP-2104673-A2 | NEW 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | Sanofi-Aventis (FR) | 2009-09-30 | — | — | EP | claimed |
| WO-2008099072-A2 | NEW 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2008-08-21 | — | — | WO | claimed |
| US-20100035907-A1 | NEW 2,4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| US-20100035907-A1 | NEW 2,4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| EP-2104673-A2 | NEW 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | Sanofi-Aventis (FR) | 2009-09-30 | — | — | EP | disclosed |
| WO-2008099072-A2 | NEW 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035907-A1 | NEW 2,4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | IKBKB, CDK2, IKBKE | KMT2A 1528/4885MEN1 4141/4885L3MBTL1 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.